Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7776381 | 0.87 | RAB9A (0.67) | RAB9AL3MBTL1NPC1TSHRMAPK1 | |
| SCHEMBL13232422 | 0.84 | L3MBTL1 (0.59) | RAB9AL3MBTL1NPC1LMNASMN1; SMN2 | |
| SCHEMBL7772856 | 0.84 | MAOB (0.43) | RAB9AL3MBTL1LMNASMN1; SMN2HPGD | |
| SCHEMBL22000731 | 0.82 | RAB9A (0.78) | RAB9AL3MBTL1NPC1TSHRMAPK1 | |
| SCHEMBL7768873 | 0.79 | RAB9A (0.68) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL7772783 | 0.79 | FYN (0.43) | RAB9AL3MBTL1NPC1TSHRMAPK1 | |
| SCHEMBL15560656 | 0.77 | RAB9A (0.50) | RAB9AL3MBTL1NPC1TSHRMAPK1 | |
| SCHEMBL15554875 | 0.76 | RAB9A (0.49) | RAB9AL3MBTL1NPC1TSHRMAPK1 | |
| SCHEMBL15555874 | 0.76 | RAB9A (0.49) | RAB9AL3MBTL1NPC1TSHRMAPK1 | |
| SCHEMBL13232430 | 0.76 | CYP11B1 (0.61) | RAB9AL3MBTL1NPC1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2010-07-01 | — | — | US | disclosed |
| EP-0788487-B1 | PROCESS FOR THE PREPARATION OF TETRAZOLES | NOVARTIS AG (CH) | 2001-07-25 | — | — | EP | disclosed |
| EP-0788487-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLES | Novartis AG (CH) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013489-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLES | NOVARTIS AG (CH) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | AGTR1, AGTR2, AGT | RAB9A 2815/4885L3MBTL1 4839/4885NPC1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.